SCHEMBL1528792

SCHEMBL1528792

CN(C)C=N/N=C/N(C)C

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.33
RECQL P46063 1/20 0.33
TSHR P16473 1/20 0.33
TAS2R38 P59533 1/20 0.33
BCAT1 P54687 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563339 1.00 ALOX15 (0.33) ALOX15RECQLTSHRTAS2R38BCAT1
SCHEMBL31231602 1.00 ALOX15 (0.33) ALOX15RECQLTSHRTAS2R38BCAT1
SCHEMBL563340 1.00 ALOX15 (0.33) ALOX15RECQLTSHRTAS2R38BCAT1
SCHEMBL14556333 1.00 ALOX15 (0.33) ALOX15RECQLTSHRTAS2R38BCAT1
Hydrochloric Acid SCHEMBL3065209 0.96 ALOX15 (0.32) ALOX15RECQLTSHRTAS2R38
Hydrochloric Acid SCHEMBL3597570 0.96 ALOX15 (0.32) ALOX15RECQLTSHRTAS2R38
Hydrochloric Acid SCHEMBL2659325 0.96 ALOX15 (0.32) ALOX15RECQLTSHRTAS2R38
SCHEMBL19773677 0.86
SCHEMBL13866900 0.83
Hydrochloric Acid SCHEMBL9487889 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-20 US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 WO disclosed
WO-2023081328-A1 HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF VALO HEALTH, INC. (US) 2023-05-11 WO disclosed
EP-3131897-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2022-06-15 EP disclosed
US-11053241-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-07-06 US disclosed
EP-2742047-B1 ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-05-12 EP disclosed
US-20080153851-A1 Cycloalkyl Piperidine Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2008-06-26 US disclosed
US-20080076783-A1 Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists MERCK & CO., INC. (US) 2008-03-27 US disclosed
US-20080009518-A1 5-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US disclosed
WO-2007075598-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-07-05 WO disclosed
US-7217714-B1 CCR5 modulators AGOURON PHARMACEUTICALS, INC. (US) 2007-05-15 US disclosed
EP-1636181-A1 SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands ZIARCO INC. 2005-12-01 US disclosed
EP-1157002-B1 1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2005-08-10 EP disclosed
WO-2005000809-A1 SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES MERCK & CO., INC. (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ALOX15 2684/4885RECQL 2795/4885TSHR 264/4885
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 ALOX15 3808/4885RECQL 1421/4885TSHR 1652/4885
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS ALOX15 2581/4885RECQL 910/4885TSHR 3881/4885
US-20080009518-A1 5-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists TACR1, HTR5A, TACR2 ALOX15 1276/4885RECQL 344/4885TSHR 1569/4885
US-11053241-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 ALOX15 3808/4885RECQL 1421/4885TSHR 1652/4885
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT ALOX15 429/4885RECQL 2332/4885TSHR 2488/4885
US-20080153851-A1 Cycloalkyl Piperidine Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 ALOX15 1668/4885RECQL 3024/4885TSHR 1182/4885
US-20080076783-A1 Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 ALOX15 1152/4885RECQL 3492/4885TSHR 1460/4885
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands HRH4, HRH3, TLR4 ALOX15 1782/4885RECQL 3676/4885TSHR 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.